I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center.
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center.
Transcript
What challenges are you faced with in the treatment of patients with advanced and/or recurrent endometrial cancer?
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor for advanced endometrial cancers. You know, the overall 5-year survival is anywhere from 15% to 40%, depending on hat study you have, and we don’t have a very long list of agents, cytotoxics or targeted agents, that endometrial cancer responds to. Recurrent disease is even more dismal for endometrial cancer with actually survival after the diagnosis of recurrence being only between 14 and 15 months.
So, I think the hardest thing is that we don’t have many good treatments to offer advanced and recurrent endometrial cancer patients once we get passed paclitaxel and carboplatin. So, I think that’s the hardest thing to tell patients, that we don’t have as many options as we would like for them to be treated with.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More